Aroa Biosurgery Poised to Gain From US Reimbursement Shift as New Data Backs Myriad

Aroa Biosurgery Ltd ( (AU:ARX) ) has shared an update.

Aroa Biosurgery says its Symphony wound-care product is well placed to benefit from new US Medicare rules that set a single outpatient reimbursement rate of US$127.14 per square centimetre for skin substitutes, a move the company expects will squeeze out higher-priced rivals and support Symphony’s uptake in hospital outpatient departments where it already has inpatient relationships. The company also highlighted new clinical data from its MASTRR registry showing that Myriad achieves rapid vascularised tissue coverage in complex trauma cases with low complication and application rates compared with competing bioscaffolds, reinforcing its potential to lower total care costs, and reaffirmed FY26 guidance with revenue expected near the top of its NZ$92–100 million range and normalised EBITDA of NZ$5–8 million, underpinned by strong sales momentum and a favourable US reimbursement backdrop.

The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

More about Aroa Biosurgery Ltd

Aroa Biosurgery Limited is a New Zealand-based soft tissue regeneration company listed on the ASX that develops and commercialises bioscaffold products such as Symphony and Myriad, targeting wound care, trauma and complex reconstructive surgery, with a strong commercial focus on the US hospital and outpatient markets.

Average Trading Volume: 223,070

Technical Sentiment Signal: Sell

Current Market Cap: A$215.6M

See more data about ARX stock on TipRanks’ Stock Analysis page.